Telomir Pharmaceuticals Azioni (NASDAQ: TELO)

Ultime notizie per Telomir Pharmaceuticals (NASDAQ:TELO) Azioni

Telomir Pharmaceuticals

Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals Inc

TELO GENOMICS CORP by Telo Genomics Corp.

Telo Genomics Corp

Telos - United States Dollar

Telos Corp

Pseudonymous Polymarket trader ‘Redegen&#8216; ended Election Day down $6.7 million, marking a dramatic setback in his high-stakes political betting after <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">Donald Trump won re-election</a>.
What Happened: Redegen, now going by &#8220;theRealTaylorSwift&#8221; on prediction market Polymarket, placed substantial bets on Kamala Harris winning the popular vote and the presidency, acquiring a massive 9.2 million shares on Harris winning the popular vote and 2.6 million shares on her winning the presidency. Although he anticipated a Trump victory in the electoral college, <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41713496/kamala-harriss-whale-trader-now-up-1-2-million-predicts-data-still-pointing-to-a-trump-pre">Redegen believed that Polymarket was "systemically overweighting" Trump</a> and "underweighting" Harris, which led him to hold onto his bets.
His <a href="https://polymarket.com/profile/0x59ce25a63a7b4f3d03f25976f9cb3b2625f5cc34?tab=positions">portfolio</a> now stands at a $6.8 million loss after former President Trump secured a second term and won the popular vote. The former President&#8217;s chances to do so were rated around 25% before votes started being counted.
Another notable loser betting on Harris was spotted by Lookonchain <a href="https://x.com/lookonchain/status/1854047790856650754">data</a>. Polymarket trader &#8216;leier&#8217; spent 5 million USDC on November 4 betting on Kamala Harris winning the U.S. election. His current loss stands at $4.9 million.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41770352/bitcoins-future-under-president-elect-donald-trump-a-look-at-his-crypto-policies">Bitcoin&#8217;s Future Under President-Elect Donald Trump: A Look At His Crypto Policies</a>
Why It Matters: Redegen's strategy and losses have sparked discussions within the crypto trading community. Despite his substantial loss, he <a href="https://x.com/redegencom/status/1854079503011635350">expressed gratitude for the experience</a> and praised prediction platforms for maintaining a fair environment.
Despite his data pointing to a Trump presidency, he had chosen not to offload shares on Polymarket due to this perceived systemic overweighting.
His high-stakes gamble serves as a stark reminder of the volatility and risk associated with prediction markets and crypto trading.
What&#8217;s Next: The influence of prediction markets is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41766547/trump-gives-victory-speech-in-florida-as-winning-pennsylvania-puts-him-at-brink-of-victory-vows-to-f">Trump Gives Victory Speech In Florida As Winning Pennsylvania Puts Him At Brink Of Victory, Vows To &#8216;Fix Everything About Our Country&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Kamala Harris's Biggest Polymarket Backer Loses $6.7 Million As Donald Trump Secures The Popular Vote Against The Odds

BMO Capital analyst Etienne Ricard maintains Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Outperform and raises the price target from $138 to $157.

Price Target

Analyst Ratings

BMO Capital Maintains Outperform on Apollo Global Management, Raises Price Target to $157

Wells Fargo analyst Michael Sison maintains Huntsman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>) with a Overweight and lowers the price target from $26 to $25.

Wells Fargo Maintains Overweight on Huntsman, Lowers Price Target to $25

RBC Capital analyst Sabahat Khan maintains Toromont Industries (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TIH#TSX">TIH</a>) with a Outperform and lowers the price target from C$142 to C$138.

TSX:TIH

RBC Capital Maintains Outperform on Toromont Industries, Lowers Price Target to C$138

BMO Capital analyst Michael Zaremski maintains Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) with a Market Perform and raises the price target from $98 to $104.

ACGL

BMO Capital Maintains Market Perform on Arch Capital Group, Raises Price Target to $104

RBC Capital analyst Maurice Choy maintains TransAlta (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TA#TSX">TA</a>) with a Outperform and raises the price target from C$14 to C$16.

TSX:TA

RBC Capital Maintains Outperform on TransAlta, Raises Price Target to C$16

Bitcoin&nbsp;(CRYPTO:&nbsp;<a href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining stocks&nbsp;MARA Holdings&nbsp;Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>),&nbsp;Riot Platforms&nbsp;Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>)&nbsp;and&nbsp;CleanSpark&nbsp;Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) are surging Wednesday morning after Donald Trump was elected as the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41770352/bitcoins-future-under-president-elect-donald-trump-a-look-at-his-crypto-policies">next president of the United States</a>.
What To Know: Broader markets are ripping higher in early trading Wednesday after Trump secured a second term as investors expect U.S.-focused companies to benefit from potential lower taxes and tariffs.
Crypto markets appear to be among the biggest immediate beneficiaries with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) hitting new all-time highs above $75,000 and several other popular cryptocurrencies surging on the election results. Trump has positioned himself as a pro-crypto candidate.
Bitcoin mining stocks are outpacing gains in underlying cryptocurrencies in early trading Wednesday. Trump said earlier this year that he wanted all Bitcoin <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39289772/donald-trump-wants-all-the-remaining-bitcoin-to-be-made-in-the-usa">to be made in the U.S.</a>
Check This Out: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41770352/bitcoins-future-under-president-elect-donald-trump-a-look-at-his-crypto-policies">Bitcoin&#8217;s Future Under President-Elect Donald Trump: A Look At His Crypto Policies</a>
MARA Holdings, Riot and CleanSpark all released&nbsp;<a href="https://www.benzinga.com/pressreleases/24/11/n41714046/cleanspark-releases-october-2024-bitcoin-mining-update">mining updates for October</a> at the beginning of the week. Here&#8217;s a look at how the miners stack up against each other.
<ul>
<li>MARA Holdings mined 717 bitcoin in October, up 2% month-over-month. The company said it held a total of 27,562 bitcoin as of Oct. 31.</li>
</ul>
<ul>
<li>Riot mined 505 bitcoin in October, up 23% month-over-month. The company said it held 10,928 bitcoin as of the end of the month.</li>
</ul>
<ul>
<li>CleanSpark mined 655 bitcoin in October, up 32% on a month-over-month basis. The company had total bitcoin holdings of 8,701 as of Oct. 31.</li>
</ul>
Bitcoin was up about 7% over a 24-hour period, trading around $74,640 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
MARA, RIOT, CLSK: At publication time, MARA shares were up 9.21% at $17.73, Riot shares were up 12.3% at $10.90 and CleanSpark shares were up 11.6% at $11.74, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

$BTC

CLSK

MARA

RIOT

Bitcoin Mining Stocks MARA Holdings, Riot Platforms And CleanSpark Are Charging Higher Wednesday: What's Going On?

Wells Fargo analyst Michael Sison maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Overweight and raises the price target from $105 to $107.

Wells Fargo Maintains Overweight on DuPont de Nemours, Raises Price Target to $107

Wells Fargo analyst Joseph O'Dea maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Overweight and raises the price target from $128 to $135.

Wells Fargo Maintains Overweight on Emerson Electric, Raises Price Target to $135

Movie theater company AMC Entertainment Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) could highlight market share gains and a strong box office performance when the company reports third-quarter financial results Wednesday<a href="https://www.benzinga.com/earnings"> after the market close.</a>
AMC Earnings Estimates: Analysts expect AMC to report third-quarter revenue of $1.33 billion, down from $1.41 billion in last year's third quarter, according to data <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company has beaten revenue estimates from analysts in nine of the last 10 quarters, missing in the most recently reported second quarter.
Analysts expect the company to report a loss of 11 cents per share, compared to a loss of 9 cents per share in last year's third quarter. The company has beaten analyst estimates for earnings per share in seven of the last eight quarters, meeting expectations in the most recently reported second quarter.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/09/41073813/amc-survival-against-challenging-sector-brings-magic-comparison-harry-houdini-works-at-amc">AMC Survival Against Challenging Sector Brings Magic Comparison: &#8216;Harry Houdini Works At AMC&#8217;</a>
What AMC Analysts Are Saying: Wedbush analyst Alicia Reese <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40165453/amc-stock-to-remain-volatile-after-q2-results-analysts-praise-market-share-gains-ca">detailed the company's</a> potential market share gains in an investor note after second-quarter financial results.
The analyst, who has a Neutral rating and a $4 price target, said the company needs to reduce its high debt load to help with future growth.
"AMC can also drive revenue growth in Europe with theater upgrades. However, it is unlikely to do so until it works through balance sheet right-sizing," Reese said.
The analyst said a large network of premium screens and concert movie distribution deals could help "justify its premium valuation," but cautioned on more potential capital needed to cover interest payments.
&#8220;We expect AMC&#8217;s shares to remain volatile as its shareholders dislike its frequent share issuances.&#8221;
Benchmark analyst Mike Hickey said AMC's second quarter saw a strong performance with several box office hits.
The analyst, who has a Market Weight rating and no price target, said the concession revenue per attendee was up in the second quarter for domestic theaters along with higher average ticket prices, positives for the company.
Key Items to Watch From AMC: The third-quarter box office rose 0.6% year-over-year domestically according to <a href="https://www.boxofficemojo.com/quarter/q3/?grossesOption=calendarGrosses">data </a>from BoxOfficeMojo. The quarter saw hit films like "Deadpool &amp; Wolverine," "Despicable Me 4," "Twisters" and "Beetlejuice Beetlejuice" released.
AMC's quarterly report comes after peer Cinemark Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) <a href="https://www.benzinga.com/news/earnings/24/10/41660851/whats-going-on-with-cinemark-holdings-stock-thursday">reported quarterly earnings </a>that saw earnings per share and revenue both beat analyst estimates. The company&#8217;s shares rose after the report, and analysts raised<a href="https://www.benzinga.com/quote/CNK/analyst-ratings"> their price targets.</a>
Cinemark said the third quarter box office exceeded expectations and was the highest quarterly total since the COVID-19 pandemic.
A similar report from AMC could go a long way toward showing a box office recovery and growth ahead.
Fourth-quarter domestic box office hasn't been as strong, with "Venom: The Last Dance" the current top film of the quarter at $92.0 million. Upcoming movies like "Gladiator II," "Moana 2," "Wicked," "Sonic the Hedgehog 3" and "Mufasa: The Lion King" could bring optimism for a strong end to the year for movie theater companies.
AMC CEO Adam Aron has been more optimistic about upcoming years than 2024, which could be echoed in his commentary on Wednesday.
&#8220;With a long list of blockbuster movie titles opening in theaters during the remainder of the year and into 2025 and 2026, the industry-wide box office now appears to us to be poised for sustained growth. Looking ahead, we believe that bodes ever so well for the increasing cash generation potential from AMC&#8217;s movie theaters both at home and abroad," Aron said earlier this year.
AMC Price Action: AMC stock was up 2.3% to $4.50 on Wednesday versus a 52-week trading range of $2.38 to $11.88. AMC stock is down 28% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/05/39010959/amc-ceo-says-were-still-here-how-taylor-swift-popcorn-buckets-help-movie-theater-from-going">AMC CEO Says &#8216;We&#8217;re Still Here&#8217;: How Taylor Swift, Popcorn Buckets Help Movie Theater From Going &#8216;Kaplooey&#8217;</a></li>
</ul>
Photo: Shutterstock

Entertainment

Previews

Trading Ideas

AMC Q3 Earnings Preview: Can 'Deadpool & Wolverine' Box Office Strength Lift Stock?

Wells Fargo analyst Jason Haas maintains UL Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>) with a Overweight and raises the price target from $56 to $62.

Wells Fargo Maintains Overweight on UL Solutions, Raises Price Target to $62

<a href="https://thebearcave.substack.com/p/problems-at-viasat-vsat" title="https://thebearcave.substack.com/p/problems-at-viasat-vsat">https://thebearcave.substack.com/p/problems-at-viasat-vsat</a>

VSAT

Watching Viasat; The Bear Cave Newsletter Issues Report Titled 'Problems at Viasat (VSAT)'

Susquehanna analyst Christopher Rolland maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Neutral and lowers the price target from $260 to $250.

NXPI

Susquehanna Maintains Neutral on NXP Semiconductors, Lowers Price Target to $250

Wells Fargo analyst Jason Haas maintains Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) with a Underweight and raises the price target from $460 to $470.

Wells Fargo Maintains Underweight on Gartner, Raises Price Target to $470

Susquehanna analyst Christopher Rolland maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Positive and lowers the price target from $95 to $90.

MCHP

Susquehanna Maintains Positive on Microchip Technology, Lowers Price Target to $90

Financial giants have made a conspicuous bearish move on Freeport-McMoRan. Our analysis of options history for Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) revealed 16 unusual trades.
Delving into the details, we found 31% of traders were bullish, while 56% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $57,912, and 14 were calls, valued at $1,995,172.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $33.0 and $50.0 for Freeport-McMoRan, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Freeport-McMoRan's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Freeport-McMoRan's whale activity within a strike price range from $33.0 to $50.0 in the last 30 days. 
<h3>Freeport-McMoRan Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907075_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.6</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$50.00</td>
<td>$520.3K</td>
<td>35.4K</td>
<td>5.1K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.54</td>
<td>$1.43</td>
<td>$1.5</td>
<td>$50.00</td>
<td>$506.2K</td>
<td>35.4K</td>
<td>10.7K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$1.54</td>
<td>$1.51</td>
<td>$1.51</td>
<td>$50.00</td>
<td>$204.1K</td>
<td>35.4K</td>
<td>5.1K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.49</td>
<td>$1.48</td>
<td>$1.49</td>
<td>$50.00</td>
<td>$139.3K</td>
<td>35.4K</td>
<td>7.4K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.45</td>
<td>$1.43</td>
<td>$1.43</td>
<td>$50.00</td>
<td>$98.6K</td>
<td>35.4K</td>
<td>6.4K</td>
</tr>
</tbody>
</table>

<h3>About Freeport-McMoRan</h3>
Freeport-McMoRan Inc is an international mining company. It has organized its mining operations into four primary divisions: North America copper mines, South America mining, Indonesia mining and Molybdenum mines. Its reportable segments include the Morenci, Cerro Verde and Grasberg (Indonesia mining) copper mines, the Rod &amp; Refining operations and Atlantic Copper Smelting and Refining. It derives key revenue from the sale of Copper.
After a thorough review of the options trading surrounding Freeport-McMoRan, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Freeport-McMoRan's Current Market Status</h3>
<ul>
<li>With a volume of 3,545,458, the price of FCX is down -2.09% at $46.01. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<h3>Professional Analyst Ratings for Freeport-McMoRan</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $54.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Raymond James keeps a Outperform rating on Freeport-McMoRan with a target price of $57. 
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Perform rating on Freeport-McMoRan, which currently sits at a price target of $53. 
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Freeport-McMoRan, targeting a price of $52. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Freeport-McMoRan, targeting a price of $55. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Freeport-McMoRan, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

This Is What Whales Are Betting On Freeport-McMoRan

Financial giants have made a conspicuous bullish move on Mastercard. Our analysis of options history for Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) revealed 9 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $98,538, and 7 were calls, valued at $507,653.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $390.0 to $530.0 for Mastercard during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Mastercard stands at 232.62, with a total volume reaching 226.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Mastercard, situated within the strike price corridor from $390.0 to $530.0, throughout the last 30 days.
<h3>Mastercard Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907070_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$124.65</td>
<td>$121.65</td>
<td>$123.99</td>
<td>$400.00</td>
<td>$99.1K</td>
<td style="text-align: right;">487</td>
<td style="text-align: right;">12</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$133.4</td>
<td>$129.0</td>
<td>$129.0</td>
<td>$420.00</td>
<td>$90.4K</td>
<td style="text-align: right;">183</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$155.85</td>
<td>$153.5</td>
<td>$153.55</td>
<td>$390.00</td>
<td>$76.7K</td>
<td style="text-align: right;">33</td>
<td style="text-align: right;">12</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$150.35</td>
<td>$145.25</td>
<td>$145.25</td>
<td>$400.00</td>
<td>$72.6K</td>
<td style="text-align: right;">198</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$7.05</td>
<td>$6.9</td>
<td>$7.05</td>
<td>$520.00</td>
<td>$70.6K</td>
<td style="text-align: right;">801</td>
<td style="text-align: right;">98</td>
</tr>
</tbody>
</table>

<h3>About Mastercard</h3>
Mastercard is the second-largest payment processor in the world, having processed close to over $9 trillion in volume during 2023. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
<h3>Current Position of Mastercard</h3>
<ul>
<li>With a volume of 778,613, the price of MA is up 2.7% at $519.19. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 84 days.</li>
</ul>
<h3>Professional Analyst Ratings for Mastercard</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $565.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Macquarie keeps a Outperform rating on Mastercard with a target price of $565. 
&#x2A; An analyst from Keybanc persists with their Overweight rating on Mastercard, maintaining a target price of $580. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Mastercard, maintaining a target price of $544. 
&#x2A; Maintaining their stance, an analyst from Susquehanna continues to hold a Positive rating for Mastercard, targeting a price of $605. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Mastercard, targeting a price of $532. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Mastercard with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Mastercard Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bearish stance on Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Moderna.
This isn't normal.
The overall sentiment of these big-money traders is split between 36% bullish and 54%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $214,735, and 7 are calls, for a total amount of $478,040.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $130.0 for Moderna over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Moderna's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna's whale activity within a strike price range from $40.0 to $130.0 in the last 30 days. 
<h3>Moderna Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907065_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$1.31</td>
<td>$1.27</td>
<td>$1.31</td>
<td>$60.00</td>
<td>$107.5K</td>
<td>2.9K</td>
<td>1.6K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.55</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$50.00</td>
<td>$105.8K</td>
<td>4.7K</td>
<td>513</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$16.7</td>
<td>$16.65</td>
<td>$16.65</td>
<td>$40.00</td>
<td>$88.2K</td>
<td>40</td>
<td>150</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$17.0</td>
<td>$16.65</td>
<td>$16.65</td>
<td>$40.00</td>
<td>$78.2K</td>
<td>40</td>
<td>97</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$17.4</td>
<td>$16.65</td>
<td>$16.65</td>
<td>$40.00</td>
<td>$73.2K</td>
<td>40</td>
<td>50</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Where Is Moderna Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,021,467, with MRNA's price down by -1.31%, positioned at $52.59.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 1 days.</li>
</ul>
<h3>Professional Analyst Ratings for Moderna</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $69.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein has revised its rating downward to Market Perform, adjusting the price target to $55. 
&#x2A; An analyst from UBS persists with their Buy rating on Moderna, maintaining a target price of $108. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Underweight rating for Moderna, targeting a price of $59. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Hold rating on Moderna with a target price of $55. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

MRNA

Moderna Options Trading: A Deep Dive into Market Sentiment

<a href="https://www.cnbc.com/2024/11/06/planet-fitness-bid-for-bankrupt-blink-fitness.html" title="https://www.cnbc.com/2024/11/06/planet-fitness-bid-for-bankrupt-blink-fitness.html">https://www.cnbc.com/2024/11/06/planet-fitness-bid-for-bankrupt-blink-fitness.html</a>

PLNT

'Planet Fitness wants to acquire bankrupt budget-fitness chain Blink Holdings' - CNBC

Macro Economic Events

Econ #s

Economics

USA Gasoline Inventories 0.412M Barrel Build Vs 1.650M Barrel Draw Est.; 2.707M Barrel Draw Prior

Singapore's Mobile-health Network files for $10M US IPO

Stocks To Watch: Eyes On Broadcom, Target, Costco, Rivian And Small Caps

Affimed N.V., Hutchmed, Annexon among healthcare movers

Telomir Pharmaceuticals, Inc. (TELO) just unveiled an update. Telomir Pharmaceuticals, Inc. recently showcased their preclinical data and future st...

Telomir Pharmaceuticals Unveils Research Direction at NPC

MRIN, WISA and SMFL among mid-day movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Telomir Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/telo-stock-quote/">TELO</a>) just reported results for the first quarter of 2024.<ul><li>Telomir Pharmaceuticals reported earnings per share of -23 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/telo-stock-earnings-telomir-pharmaceuticals-for-q1-of-2024/">TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024

Investors Prep For High-Stakes Week After Tech Stocks Crumble

Wall Street Breakfast: The Week Ahead

IPO Roundup: zSpace, Actuate Therapeutics and more

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Telomir Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/telo-stock-quote/">TELO</a>) just reported results for the second quarter of 2024.<ul><li>Telomir Pharmaceuticals reported earnings per share of -5 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/telo-stock-earnings-telomir-pharmaceuticals-for-q2-of-2024/">TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q2 2024

ABNB

ACTU

AFMD

AGBA

AMCX

AMGN

AMIX

ANNX

AVGO

BPTH

CAPT

CELH

CHRO

CRWD

DAVE

DDOG

DMAAU

DRIL

EDBL

EMTX

ENVA

EXPE

FIVE

FSLY

FWRD

GILD

HEPA

HLXB

ISPO

KYTX

LUMN

MLEC

MRIN

MTTR

NKGN

OSTX

PARAA

PLMKU

PMNT

PROK

RIVN

RNXT

RWOD

SHOP

SMFL

TBBB

TELO

TRSG

TTWO

UBER

VACHU

WISA

WULF

YYGH

ZSPC

Screenshot 2024-09-04 at 6.19.41 PM

Biotech

General

MIRA

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs

Screenshot 2024-05-31 at 5.26.53 PM

From Pets To Humans, Telomir Pharmaceuticals (NASDAQ: TELO) May Hold The Key To Extending Life, Reversing Aging

Press Releases

New to The Street TV Announces Episode 575 with its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ET

Health Care

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

From Pets To Humans, Telomir Pharmaceuticals (NASDAQ: TELO) Holds The Key To Extending Life, Reversing Aging

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

Management

Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday

Comments

Telomir Pharmaceuticals

Notizie

Ultime notizie per Telomir Pharmaceuticals (NASDAQ:TELO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO